glp 1 compounding restrictions GLP-1 Compounding: When Innovation May Mean Liability GLP-1 Compounding Crackdown | Double-Helix

Laboratory monitoring should be tailored to individual risk factors and symptoms rather than performed routinely

The study found that those who had been taking semaglutide or lixisenatide for at least six months had twice the risk of developing macular degeneration, compared with similar patients who were not taking the drugs

(31 August 2025)

[DOI] [PubMed] [Google Scholar] 200.Meier J.J., Gethmann A., Nauck M.A., Gotze O., Schmitz F., Deacon C.F

MRI: magnetic resonance imaging Mechanisms of muscle loss associated with GLP-1RAs treatment Preservation of skeletal muscle is critical for metabolic health, physical function and long-term outcomes, making the study of mechanisms underlying muscle loss during GLP-1RA therapy clinically relevant